
Novo Nordisk’s weight loss drug, Wegovy, is experiencing a surge in new prescriptions following a US ban on its copycat versions, though analysts caution that more substantial growth is needed to reassure investors.
Since the US Food and Drug Administration (FDA) implemented a ban on ‘compounded’ versions of Wegovy on 22 May, new prescriptions for the drug have risen by approximately 33 per cent. This culminated in 181,200 new prescriptions in the week ending 18 July, according to IQVIA data shared with Reuters by industry analysts.